Recursion Pharma , which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths in the colon in patients with a rare ...
REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden ...
To the research team working to save him, KJ Muldoon was first known only as Patient Eta. But within months, KJ’s name — and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback